It is apparent that from the work of the authors and many others, including the work of Rivard, Sledge, Zuckerman, among others, that radiosynovectomy has an important role to play in providing effective treatnent of affected joints associated with rheumatiod arthritis and other forms of arthritis as well as the hemophiliac joint. Treatment offers relief from recurrent joint effusion with an approximately 60% to 80% favorable response and from recurrent hemarthrosis in the hemophiliac joint with an approximately 75% to 80% favorable response. The impact of providing radiosynovectomy as an alternative to surgical synovectomy seen, where postoperative side effects such as joint stiffness are avoided, improved quality of life is repeatedly documented, and the cost savings in health care dollars, particularly evident in the hemophiliac joint in this relatively small population, are potentially enormous. With almost two million people in the United States suffering from rheumatoid arthritis, the potential saving in health care dollars is also enormous. As with anf use of in vivo radiopharmaceuticals, the potential for radiotion-induced damage exist. However, with a 25 plus year record of use, more optimally configured rediopharmaceuticals, and the addition of manuevers to minimize potential joint leakage, the risk of radiation induced damaged appears to be minimal. It appears as though radiosynovectomy is an effective as well as cost- effective alternative to sutgical synovectomy and is becoming the procedure of choice particularly in the hemophiliac patient with recurrent hemarthrosis and synovitis who has failed medical theraphy. It is also the procedure of choice in patients for whom surgery is contraindicated because of the presence of clotting factor inhibitors.